PT - JOURNAL ARTICLE AU - Nicolas Banholzer AU - Eva van Weenen AU - Adrian Lison AU - Alberto Cenedese AU - Arne Seeliger AU - Bernhard Kratzwald AU - Daniel Tschernutter AU - Joan Puig Salles AU - Pierluigi Bottrighi AU - Sonja Lehtinen AU - Stefan Feuerriegel AU - Werner Vach TI - Estimating the effects of non-pharmaceutical interventions on the number of new infections with COVID-19 during the first epidemic wave AID - 10.1101/2021.01.15.21249884 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.15.21249884 4099 - http://medrxiv.org/content/early/2021/01/20/2021.01.15.21249884.short 4100 - http://medrxiv.org/content/early/2021/01/20/2021.01.15.21249884.full AB - The novel coronavirus (SARS-CoV-2) has rapidly developed into a global epidemic. To control its spread, countries have implemented non-pharmaceutical interventions (NPIs), such as school closures, gathering bans, or even stay-at-home orders. Here we study the effectiveness of seven NPIs in reducing the number of new infections, which was inferred from the reported cases of COVID-19 using a semi-mechanistic Bayesian hierarchical model. Based on data from the first epidemic wave of n = 20 countries (i.e., the United States, Canada, Australia, the EU-15 countries, Norway, and Switzerland), we estimate the relative reduction in the number of new infections attributed to each NPI. Among the NPIs considered, event bans were most effective, followed by venue and school closures, whereas stay-at-home orders and work bans were least effective. With this retrospective cross-country analysis, we provide estimates regarding the effectiveness of different NPIs during the first epidemic wave.Competing Interest StatementSF reports membership in a COVID-19 working group of the World Health Organization but without competing interest. JPS declares part-time employment at Luciole Medical outside of the submitted work. SF reports grants from the Swiss National Science Foundation outside of the submitted work. All other authors declare no competing interests.Funding StatementNB, EvW and SF acknowledge funding from the Swiss National Science Foundation (SNSF) as part of the Eccellenza grant 186932 on "Data-driven health management". The funding bodies had no control over design, conduct, data, analysis, review, reporting, or interpretation of the research conducted.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collected data from publicly available data sources (Johns Hopkins Coronavirus Resource Center for epidemiological data; news reports and government resources for policy measures). All the public health information that we used is documented in the main text, the extended data, and supplementary tables. A preprocessed data file together with reproducible code is available from https://github.com/nbanho/npi_effectiveness_first_wave. https://github.com/nbanho/npi_effectiveness_first_wave